Baseline Heterogeneity of Myeloid and Stroma Cells to Predict Pcr, Baseline Lymph Node (LN) Metastasis, and 1-Year EFS in Locally Advanced ESCC with Neoadjuvant Immunotherapy: Final Results from a Single-Arm, Phase II Clinical Trial (SEEK-01).